Management of depression/anxiety in patients with chronic liver disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 24 of the 30 sources its claims cite were checked for support.
Abstract
Export {"href":"Single Video Player","role":"media-player-id","content-type":"play-in-place","position":"float","orientation":"portrait","label":"","caption":"","object-id":[{"pub-id-type":"doi","id":""},{"pub-id-type":"other","content-type":"media-stream-id","id":"1_v7qc37hn"},{"pub-id-type":"other","content-type":"media-source","id":"Kaltura"}]}
Overview
CoChat Summary
TL;DR
This narrative review summarizes the epidemiology, pathophysiology, screening, and pharmacologic management of depression and anxiety in patients with chronic liver disease and cirrhosis. It proposes a patient-centered model of care integrating mental health screening and treatment into hepatology practice.
Key findings
- Depression and anxiety are common in cirrhosis: approximately 1 in 6 patients with cirrhosis have moderately severe to severe depression, and half have moderate to severe anxiety; in a baseline survey of 1021 patients with compensated cirrhosis across 3 US institutions, self-reported poor health, being widowed, fear of HCC, higher household income, and Hispanic ethnicity were associated with moderately severe to severe depression, while male sex, self-reported poor health, and fear of HCC were associated with high anxiety.
- Comorbid depression is linked to worse outcomes: diagnosis of cirrhosis nearly doubled the incidence of depression in the first 3 months (incidence rate ratio 1.24 before diagnosis vs 2.12 after, p<0.001), and depression is a stronger predictor of poor adherence to medical treatment.
- Screening: the authors recommend the Patient Depression Questionnaire-9 and General Anxiety Disorder-7, described as free, patient-administered tools with sensitivity >85% and specificity >76%.
- Dosing of psychotropics should be guided by Child-Turcotte-Pugh (CTP) class: most CTP-A patients tolerate 75%–100% of a standard initial dose, CTP-B patients may need a 50%–75% reduction, and CTP-C patients require close monitoring. Benzodiazepines should be avoided in patients at risk of HE except for seizures or delirium tremens, where lorazepam, temazepam, or oxazepam are preferred.
Methods
Not stated in the paper (narrative review without a described systematic search strategy, included-study selection, or primary data collection; it synthesizes cited literature and provides two summary tables and three figures). The paper reports cited epidemiologic figures from prior studies (e.g., NHANES 2005–2010 and 2007–2016, US IBM MarketScan 2016, a Korean claims cohort, and a 1021-patient multi-institution cirrhosis survey) rather than conducting its own analysis. Management recommendations are adapted from Menon et al. and other cited sources.
Limitations
The paper states no limitations. Evident from the text: it is a narrative review with no described systematic search or evidence-grading methodology; its treatment recommendations are adapted from other sources rather than derived from primary data; and several cited epidemiologic estimates come from claims databases or cross-sectional surveys, which cannot establish causality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
21 Valid · 1 Not valid · 5 Not checked · 2 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“As expected, diagnosis of cirrhosis was associated with increased incidence of depression in cohort studies: Seo and Yoo, using a claims database in Korea, that the first 3 months nearly doubled the incidence of depression (incidence rate ratio of 1.24 before the diagnosis and 2.12 after diagnosis, p<0.001).5”
What the sources say
- Supportedcites [5] 5. Seo GH, Yoo J. Incidence of major depressive disorder over time in patients with liver cirrhosis: A nationwide population-based study in korea. PLoS One. 2022;17:e0278924. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results report an IRR of 1.24 at 180–90 days before cirrhosis diagnosis and 2.12 at 30–89 days after diagnosis, both with p < 0.001. The paper used a Korean claims database and describes the post-diagnosis rise as occurring within the first three months. (LLM, conf=0.93)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Neuroinflammation is a highly correlated pathophysiological pathway to this relationship.”
What the sources say
- Partly supportedcites [8] 8. Shao Q, Wu Y, Ji J, Xu T, Yu Q, Ma C, et al. Interaction mechanisms between major depressive disorder and non-alcoholic fatty liver disease. Front Psychiatry. 2021;12:711835. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The ‘Release of Inflammatory Factors’ section suggests that inflammatory factors may link major depressive disorder and non-alcoholic fatty liver disease, and its subsection on depression discusses neuroinflammatory activity. It does not establish neuroinflammation as a highly correlated pathway between depression and cirrhosis; the liver condition examined is NAFLD. Page numbers are unavailable in our copy. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Depression and anxiety are more common among individuals with liver disease and cirrhosis compared to the general population.1,6”
What the sources say
- Partly supportedcites [1] 1. Hernaez R, Kramer JR, Khan A, Phillips J, McCallister K, Chaffin K, et al. Depression and anxiety are common among patients with cirrhosis. Clin Gastroenterol Hepatol. 2022;20:194–203.e1. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Discussion reports that depression and anxiety were common in a cohort of patients with cirrhosis. It does not compare their prevalence with the general population, and the study cohort does not establish prevalence across liver disease more broadly. Page numbers were not provided in our copy. (LLM, conf=0.86)
- Partly supportedcites [6] 6. Doyle T, Schmidt B, Scaglione S. Prevalence of depression and anxiety symptoms by liver disease etiology. Clin Liver Dis (Hoboken). 2023;22:89–94. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The introduction says depression and anxiety symptoms are prevalent in people with liver disease, and the 'Other etiologies of LD' section reports higher rates of both in some liver-disease groups than in healthy controls or the general population. The cited paper does not establish that both symptoms are more common in cirrhosis specifically, or across liver disease as a whole, than in the general population. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Berry et al14 found that each point increase in the pretransplant Montreal Cognitive Assessment was associated with 26% lower odds of post-liver transplantation cognitive impairment (adjusted OR: 0.74, 95% CI: 0.63–0.87, p<0.001), after adjusting for recipient age, history of HE, and time since liver transplantation.”
What the sources say
- Supportedcites [14] 14. Berry K, Ruck JM, Barry F, Shui AM, Cortella A, Kent D, et al. Prevalence of cognitive impairment in liver transplant recipients. Clin Transplant. 2024;38:e15229. [DOI] [PMC free article] [PubMed] [Google Scholar] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Drug dosing recommendations are guided by the Child-Turcotte-Pugh (CTP) (Table 2).16,17”
What the sources say
- Supportedcites [16] 16. Menon V, Ransing R, Praharaj SK. Management of psychiatric disorders in patients with hepatic and gastrointestinal diseases. Indian J Psychiatry. 2022;64(suppl 2):S379–93. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The ‘Severity of hepatic disease’ section describes the Child-Turcotte-Pugh classification. The ‘Drugs that escape hepatic metabolism’ section then gives dose recommendations by Child-Pugh class for the medications it discusses, supporting the claim in the context of hepatic disease. (LLM, conf=0.90)
- Could not verifycites [17] 17. Cotter TG, Beresford T. Treatment of mental health in patients with chronic liver disease. Clin Liver Dis (Hoboken). 2022;20:57–60. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Pharmacotherapy passage discusses how cirrhosis affects drug metabolism, and the antidepressant-dosing passage recommends dose adjustments for chronic liver disease. Neither passage links dosing recommendations to the Child-Turcotte-Pugh classification. Searches for Child-Turcotte-Pugh, CTP, and Child-Pugh dosing guidance found no such link in our copy; page numbers were not available. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
7 more claims · 4 with their cited sources checked
Create a free account to see all 29 claims and every source verdict.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 8
- Not yet classified. 1
Citations
Cites
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Sareen, J., Jacobi, F., Cox, B. J., Belik, S.-L., Clara, I., & Stein, M. B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2109 · Cited by 361
Russ, T. C., Kivimäki, M., Morling, J. R., Starr, J. M., Stamatakis, E., & Batty, G. D. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.004 · Cited by 110
Association of chronic liver disease with depression: A population-based study
Lee, K., Otgonsuren, M., Younoszai, Z., Mir, H. M., & Younossi, Z. M. (2013) · Psychosomatics · doi:10.1016/j.psym.2012.09.005 · Cited by 104
Depression and anxiety are common among patients with cirrhosis
Hernaez, R., Kramer, J. R., Khan, A., Phillips, J., McCallister, K., Chaffin, K., Hernandez, A. P., Fullington, H., Ortiz, C., Blackwell, J.-M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.045 · Cited by 77
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
García-Llana, H., Remor, E., del Peso, G., Celadilla, O., & Selgas, R. (2014) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-013-9383-y · Cited by 48
Vannier, A. G. L., Przybyszewski, E. M., Shay, J., Patel, S. J., Schaefer, E., Goodman, R. P., & Luther, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.001 · Cited by 38
Interaction mechanisms between major depressive disorder and non-alcoholic fatty liver disease
Shao, Q., Wu, Y., Ji, J., Xu, T., Yu, Q., Ma, C., Liao, X., Cheng, F., & Wang, X. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.711835 · Cited by 32
Kronsten, V. T., & Shawcross, D. L. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114437 · Cited by 27
Cited by
Tides of emotion: Hepatologists’ role in navigating depression and anxiety in liver disease
Khan, S., Jahagirdar, V., & Tapper, E. B. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000741 · Cited by 5
Ladner, J., Sawsan, A. I., Nofal, A., Rana, M., Ammar, M., Saba, J., & Audureau, É. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0020 · Cited by 4
Panara, A., Biliraki, D., Nußbaumer, M., Filiou, M. D., Τhomaidis, Ν. S., Kostakis, I. K., & Gikas, E. E. (2025) · Molecules · doi:10.3390/molecules30091900 · Cited by 2
Royeck, S., Meß, C., Weigel, A., Löwe, B., Toussaint, A. C., Schramm, C., Mora, M. C. S., Huber, T. B., Zeidler, C., Witte, F., et al. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01539-3 · Cited by 2
“Anxiety affects 13–75% and depression 18–72% of patients with CLD [25, 26].”
Integrative Hepatology: Enhancing overall health to manage liver disease
Lai, J. C., Tapper, E. B., & Tandon, P. (2025) · Hepatology · doi:10.1097/hep.0000000000001516 · Cited by 1
Metadata
- Authors
- Garcia-Altieri, M., Carrera-Mejias, K., & Hernaez, R.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Section of Gastroenterology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
- Venue
- Clinical Liver Disease
- Published
- 2024-01
- Volume
- 23
- Issue
- 1
- Pages
- e0179-e0179
- ISSN
- 2046-2484 (ISSN-L)
- PMC
- PMC11161294
- OpenAlex
- W4399451505
- Semantic Scholar
- 8dde94bf4e5cb7e75486bbad76b35726b8d23dc9
- Cited by
- 11
- References
- 21
- Citations by year
- 2026: 5 · 2025: 6
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Liver Disease (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depression, anxiety, chronic liver disease, psychiatric comorbidity, mental health management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of depression/anxiety in patients with chronic liver disease. https://app.cochat.ai/papers/10.1097/cld.0000000000000179
- The paper
- Garcia-Altieri, M., Carrera-Mejias, K., & Hernaez, R. (2024). Management of depression/anxiety in patients with chronic liver disease. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.